Skip to main content
. 2023 Jan 11;68(6):2252–2263. doi: 10.1007/s10620-023-07820-9

Fig. 3.

Fig. 3

Duration of exposure and risk of all-cause mortality among (a) proton pump inhibitor (PPI) users (b) histamine-2 receptor antagonist (H2RA) users, expressed as standardised mortality ratios (SMRs) and 95% confidence intervals (CI)